ASHPOfficial

Two wellness experts discuss ways that we can take care of our own well-being. They will share insights into how events in our workday interfere with wellness and what we can do to maintain and re-establish wellness. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This podcast explores the growing concern of muscle loss associated with GLP-1 receptor agonist therapy for obesity management. It highlights the need for greater awareness among clinicians and patients, emphasizing strategies such as adequate protein intake, strength training, and emerging pharmacologic options to preserve muscle mass. The discussion underscores the importance of muscle preservation for long-term health and quality of life in individuals using GLP-1 therapies.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This podcast explores how an interdisciplinary team of pharmacists, nurses, and providers redesigned frequently ignored and interruptive allergy review alerts within the electronic health record (EHR). By leveraging data from the EHR and incorporating frontline feedback, the team implemented changes to reduce noise and maintain patient safety. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Through practical discussions, expert insights, and real-world strategies, participants discuss best practices for keeping up-to-date and translating new information through practical discussions, expert insights, and real-world strategies. This podcast is designed to support pharmacists navigating rapidly evolving cardio-kidney-metabolic care. 

 The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This podcast breaks down key legislative updates and explores what they mean for new practitioners. Listeners will gain practical insight into how these changes impact day-to-day practice across care settings, along with actionable ways to apply new policies in their own roles. The episode also highlights opportunities for advocacy and engagement, empowering early-career professionals to get involved and help shape the future of the profession.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

What does the future hold for the 340B Drug Pricing Program? In this episode, ASHP Executive Vice President and CEO Sam Calabrese sits down with ASHP Chief Advocacy Officer and Vice President of Government Relations Tom Kraus to discuss what health-system pharmacy professionals are hearing on the ground, the real-world value the 340B program brings to patients and communities, and ASHP’s latest efforts to safeguard the program. Tune in for an inside look at the challenges, opportunities, and advocacy shaping the road ahead.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

T-cell-engaging bispecific antibodies represent a major therapeutic and scientific advancement in the treatment of several types of cancer. However, they carry a risk of some unique acute toxicities, such as cytokine release syndrome and neurologic toxicity. This podcast reviews this emerging drug class and strategies for recognition and management of their unique adverse events.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

This episode explores the development of an innovative telehealth‑focused, virtual postgraduate year 2 ambulatory care residency program within the VA, highlighting how it expands access to specialized training, leverages a virtual precepting model, and prepares pharmacists for emerging virtual care roles. Speakers share insights and lessons learned from designing a virtual residency model, including strategies for overcoming implementation challenges and supporting resident success. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

BiTEs or bispecific T-cell engager antibodies are an emerging class of therapies with significant potential to advance cancer treatment. Pharmacists will play a key role both in the utilization of these agents but also in the mitigation and management of the unique toxicities that accompany them. This podcast provides insights into the patient care needs and novel interdisciplinary models employed to support patients receiving BiTE therapies. Listeners will gain key insights into BiTE therapies, including their role in treatment, the current pipeline, and safety considerations.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Five recipients of the 2025 ASHP Foundation Literature Awards discuss their projects and approaches to pharmacy research.

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.